Julie A Johnson

List of Publications by Year
in descending order

113 papers	6,473 citations	94433 37 h-index	74163 75 g-index
115 all docs	115 docs citations	115 times ranked	9144 citing authors

#	Article	IF	Citations
1	Î²1â€receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery. Clinical and Translational Science, 2022, 15, 619-625.	3.1	3
2	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology and Therapeutics, 2022, 112, 959-967.	4.7	166
3	Comparison of Data Normalization Strategies for Array-Based MicroRNA Profiling Experiments and Identification and Validation of Circulating MicroRNAs as Endogenous Controls in Hypertension. Frontiers in Genetics, 2022, 13, 836636.	2.3	4
4	Impact of the ABCDâ€GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multiâ€Site, Realâ€World Investigation. Clinical Pharmacology and Therapeutics, 2022, 112, 146-155.	4.7	7
5	A Randomized, Crossâ€over Trial of Metoprolol Succinate Formulations to Evaluate <scp>PK</scp> and <scp>PD</scp> Endpoints for Therapeutic Equivalence. Clinical and Translational Science, 2022, , .	3.1	1
6	Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study. Genes, 2022, 13, 1260.	2.4	1
7	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clinical Pharmacology and Therapeutics, 2021, 109, 1417-1423.	4.7	157
8	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715.	4.7	25
9	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	2.2	63
10	Tribute to Professor Hartmut Derendorf â€•1953 to 2020: Driving force in Clinical Pharmacology and Mentor Extraordinaire. Clinical Pharmacology and Therapeutics, 2021, 109, 805-809.	4.7	0
11	Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. Genetics in Medicine, 2021, 23, 1185-1191.	2.4	17
12	Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease. Pharmacogenomics Journal, 2021, 21, 657-663.	2.0	7
13	Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. American Journal of Medicine, 2021, 134, 918-925.e2.	1.5	3
14	How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial. Clinical Pharmacology and Therapeutics, 2021, 110, 677-687.	4.7	39
15	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genetics in Medicine, 2021, 23, 2335-2341.	2.4	32
16	Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network. Journal of Personalized Medicine, 2021, 11, 647.	2.5	13
17	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genomeâ€Wide Interaction Metaâ€Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. Clinical Pharmacology and Therapeutics, 2021, 110, 723-732.	4.7	6
18	Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. Metabolites, 2021, 11, 645.	2.9	7

#	Article	IF	Citations
19	A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. Genetics in Medicine, 2021, 23, 621-628.	2.4	17
20	Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 343-351.	1.0	1
21	Clinical Pharmacology Education â€“ The Decade Ahead. Clinical Pharmacology and Therapeutics, 2020, 107, 37-39.	4.7	10
22	Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. American Journal of Hypertension, 2020, 33, e2-e2.	2.0	0
23	Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. American Journal of Hypertension, 2020, 33, 316-324.	2.0	5
24	A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications. Clinical Pharmacology and Therapeutics, 2020, 108, 116-125.	4.7	17
25	The Patientâ€Centered Future of Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2020, 107, 72-75.	4.7	6
26	Clinical Utility of Pharmacogene Panelâ€Based Testing in Patients Undergoing Percutaneous Coronary Intervention. Clinical and Translational Science, 2020, 13, 473-481.	3.1	9
27	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. Genetics in Medicine, 2020, 22, 1898-1902.	2.4	9
28	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotypeâ€Derived Activity Scores. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 678-685.	2.5	13
29	Pharmacogenetic factors affecting Î²-blocker metabolism and response. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 953-964.	3.3	20
30	Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic. Journal of Clinical Medicine, 2020, 9, 2274.	2.4	29
31	How to Transition from Singleâ€Gene Pharmacogenetic Testing to Preemptive Panelâ€Based Testing: A Tutorial. Clinical Pharmacology and Therapeutics, 2020, 108, 557-565.	4.7	24
32	What will be your legacy in pharmacy? How will you be a Paul Parker?. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 6-7.	1.0	0
33	Sorting nexin 1 loss results in increased oxidative stress and hypertension. FASEB Journal, 2020, 34, 7941-7957.	0.5	8
34	A case for genotype-guided pain management. Pharmacogenomics, 2019, 20, 705-708.	1.3	3
35	Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals. Hypertension, 2019, 74, 614-622.	2.7	14
36	Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS ONE, 2019, 14, e0221957.	2.5	7

#	Article	IF	Citations
37	CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genetics in Medicine, 2019, 21, 1842-1850.	2.4	96
38	Î²₂â€Adrenergic Receptor Gene Affects the Heart Rate Response of Î²â€Blockers: Evidence From 3 Clinical Studies. Journal of Clinical Pharmacology, 2019, 59, 1462-1470.	2.0	9
39	Challenges and lessons learned from clinical pharmacogenetic implementation of multiple geneâ€“drug pairs across ambulatory care settings. Genetics in Medicine, 2019, 21, 2264-2274.	2.4	50
40	Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. American Journal of Hypertension, 2019, 32, 668-675.	2.0	9
41	Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. European Journal of Pharmaceutical Sciences, 2019, 131, 93-98.	4.0	13
42	Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Scientific Reports, 2019, 9, 17323.	3.3	5
43	Essential Characteristics of Pharmacogenomics Study Publications. Clinical Pharmacology and Therapeutics, 2019, 105, 86-91.	4.7	9
44	Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. Journal of Clinical Hypertension, 2019, 21, 91-101.	2.0	14
45	Qualitative study of system-level factors related to genomic implementation. Genetics in Medicine, 2019, 21, 1534-1540.	2.4	26
46	Novel Implementation of Genotypeâ€Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial. Clinical and Translational Science, 2019, 12, 172-179.	3.1	22
47	Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
48	Genome-wide association analysis of common genetic variants of resistant hypertension. Pharmacogenomics Journal, 2019, 19, 295-304.	2.0	16
49	Genomeâ€Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to Î²â€Blockers. Journal of the American Heart Association, 2018, 7, .	3.7	18
50	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 447-460.	3.3	144
51	Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned. Clinical and Translational Science, 2018, 11, 175-181.	3.1	32
52	Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. Journal of Translational Medicine, 2018, 16, 92.	4.4	41
53	Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. Journal of the American Heart Association, 2018, 7, .	3.7	13
54	Multisite Investigation of Outcomes WithÂImplementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 181-191.	2.9	213

#	Article	IF	Citations
55	Whole Transcriptome Profiling: An RNAâ€Seq Primer and Implications for Pharmacogenomics Research. Clinical and Translational Science, 2018, 11, 153-161.	3.1	10
56	Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide. Pharmacogenetics and Genomics, 2018, 28, 251-255.	1.5	6
57	Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Medical Genomics, 2018, 11, 55.	1.5	6
58	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics, 2018, 50, 524-537.	21.4	1,124
59	Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nature Genetics, 2017, 49, 1113-1119.	21.4	260
60	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	11.4	84
61	Institutional profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics, 2017, 18, 421-426.	1.3	64
62	Pharmacogenetic Associations of Î²1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke, 2017, 48, 1337-1343.	2.0	24
63	Genetic variation at 16q24.2 is associated with small vessel stroke. Annals of Neurology, 2017, 81, 383-394.	5.3	73
64	Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. Journal of Clinical Hypertension, 2017, 19, 1301-1308.	2.0	11
65	Genetic Variants Associated With Uncontrolled Blood Pressure onÂThiazide Diuretic/Î²â€Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)Âand INVEST (International Verapamilâ€SR Trandolapril Study) Trials. Journal of the American Heart Association, 2017, 6, .	3.7	15
66	Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. Hypertension, 2017, 69, 51-59.	2.7	34
67	Genome-wide study of resistant hypertension identified from electronic health records. PLoS ONE, 2017, 12, e0171745.	2.5	36
68	A Genetic Response Score for Hydrochlorothiazide Use. Hypertension, 2016, 68, 621-629.	2.7	21
69	Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. American Journal of Hypertension, 2016, 29, 1186-1194.	2.0	8
70	Pharmacists should jump onto the clinical pharmacogenetics train. American Journal of Health-System Pharmacy, 2016, 73, 2013-2016.	1.0	9
71	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics, 2016, 12, 1.	3.0	10
72	Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course. American Journal of Pharmaceutical Education, 2016, 80, 122.	2.1	43

#	Article	IF	Citations
73	Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. Metabolomics, 2016, 12, 1.	3.0	14
74	Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to Î²-Blockers in Hypertensive African Americans. Hypertension, 2016, 67, 556-563.	2.7	41
75	Mechanisms and pharmacogenetic signals underlying thiazide diuretics blood pressure response. Current Opinion in Pharmacology, 2016, 27, 31-37.	3.5	19
76	Identification of Suitable Endogenous Normalizers for qRT-PCR Analysis of Plasma microRNA Expression in Essential Hypertension. Molecular Biotechnology, 2016, 58, 179-187.	2.4	33
77	Hypertension pharmacogenomics: in search of personalized treatment approaches. Nature Reviews Nephrology, 2016, 12, 110-122.	9.6	90
78	The IGNITE network: a model for genomic medicine implementation and research. BMC Medical Genomics, 2015, 9, 1.	1.5	189
79	PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. Journal of Hypertension, 2015, 33, 2278-2285.	0.5	38
80	Pharmacogenomics of Hypertension: A Genomeâ€Wide, Placeboâ€Controlled Crossâ€Over Study, Using Four Classes of Antihypertensive Drugs. Journal of the American Heart Association, 2015, 4, e001521.	3.7	74
81	CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study. Journal of the American Heart Association, 2015, 4, e001652.	3.7	44
82	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies. Journal of the National Cancer Institute, 2015, 107, dju437-dju437.	6.3	12
83	Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics. Stem Cells Translational Medicine, 2015, 4, 1380-1390.	3.3	36
84	Warfarin pharmacogenetics. Trends in Cardiovascular Medicine, 2015, 25, 33-41.	4.9	128
85	A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication. PLoS ONE, 2015, 10, e0113808.	2.5	30
86	Abstract 15465: Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). Circulation, 2015, 132, .	1.6	0
87	Largeâ€Scale Geneâ€Centric Analysis Identifies Polymorphisms for Resistant Hypertension. Journal of the American Heart Association, 2014, 3, e001398.	3.7	32
88	Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci. American Journal of Human Genetics, 2014, 94, 349-360.	6.2	158
89	Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. Diabetes Research and Clinical Practice, 2014, 104, 363-369.	2.8	3
90	Baseline predictors of central aortic blood pressure: A PEAR substudy. Journal of the American Society of Hypertension, 2014, 8, 152-158.	2.3	10

#	Article	IF	Citations
91	Clinical pharmacogenetics implementation: Approaches, successes, and challenges. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 56-67.	1.6	162
92	Institutional Profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics, 2013, 14, 723-726.	1.3	76
93	Genomic Association Analysis of Common Variants Influencing Antihypertensive Response to Hydrochlorothiazide. Hypertension, 2013, 62, 391-397.	2.7	96
94	Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol. American Journal of Hypertension, 2012, 25, 359-365.	2.0	12
95	Academia at the crossroads: education and training in pharmacogenomics. Personalized Medicine, 2012, 9, 497-506.	1.5	15
96	Advancing management of hypertension through pharmacogenomics. Annals of Medicine, 2012, 44, S17-S22.	3.8	41
97	Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. Journal of Translational Medicine, 2012, 10, 47.	4.4	22
98	Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenetics and Genomics, 2011, 21, 42-49.	1.5	52
99	Plasma Renin Activity Predicts Blood Pressure Responses to Â-Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for Hypertension. American Journal of Hypertension, 2010, 23, 1014-1022.	2.0	91
100	Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. American Heart Journal, 2009, 157, 442-449.	2.7	119
101	Ethnic Differences in Cardiovascular Drug Response. Circulation, 2008, 118, 1383-1393.	1.6	175
102	A Summer Research Training Program to Foster PharmD Students' Interest in Research. American Journal of Pharmaceutical Education, 2008, 72, 23.	2.1	31
103	KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenetics and Genomics, 2007, 17, 719-729.	1.5	65
104	Pharmacogenetics of Î²-Blockers. Pharmacotherapy, 2007, 27, 874-887.	2.6	132
105	Factors Influencing Blood Pressure Response to Trandolapril Add-On Therapy in Patients Taking Verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). American Journal of Cardiology, 2007, 99, 1549-1554.	1.6	22
106	Use of pharmacogenetics in clinical medicine: hype or hope?. Personalized Medicine, 2005, 2, 279-282.	1.5	4
107	Î²-adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure*. Clinical Pharmacology and Therapeutics, 2005, 77, 127-137.	4.7	116
108	Pharmacokinetics and genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clinical Pharmacology and Therapeutics, 2004, 76, 536-544.	4.7	134

#	Article	IF	Citations
109	Pharmacogenetics: potential for individualized drug therapy through genetics. Trends in Genetics, 2003, 19, 660-666.	6.7	90
110	Î²1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clinical Pharmacology and Therapeutics, 2003, 74, 44-52.	4.7	269
111	Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharmaceutical Research, 2002, 19, 1779-1787.	3.5	67
112	Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response. Annual Review of Genomics and Human Genetics, 2001, 2, 9-39.	6.2	365
113	Determination of Human ??2-Adrenoceptor Haplotypes by Denaturation Selective Amplification and Subtractive Genotyping. Molecular Diagnosis and Therapy, 2001, 1, 315-322.	3.3	11